Key result
Multiple pathogenic TTR variants show false-negative bone scintigraphy, including p.Val142Ile in ~10% of carriers.
Why the study?
Bone scintigraphy with 99mTc-labeled tracers is the cornerstone of noninvasive diagnosis for ATTR-CA, yet several hereditary TTR variants are associated with false-negative or low-grade tracer uptake, motivating an effort to identify all such variants and discuss their clinical implications.
Systematic Review (n=108)
Bone scintigraphy can yield false-negative results (Perugini grade 0–1) in 13 specific hereditary TTR variants (most notably p.Val50Met, p.Phe84Leu, and p.Ser97Tyr), meaning a negative scan does not exclude cardiac involvement and requires multimodal diagnostic strategies including CMR and histology.
Answers are grounded in this paper and cite their sources.
Negative scintigraphy does not exclude cardiac ATTR in hereditary cases; extends false-negative variant spectrum and supports multimodal confirmation.
Background Transthyretin cardiac amyloidosis (ATTR-CA) is characterized by amyloid deposition and frequently leads to a progressive cardiomyopathy with poor prognosis. Bone scintigraphy with 99mTc-labeled tracers is the cornerstone of noninvasive diagnosis, yet several hereditary TTR variants are associated with false-negative or low-grade tracer uptake.Objectives To identify all TTR variants associated with false-negative bone scintigraphy in hereditary ATTR-CA and discuss clinical implications.Methods Medline, Scopus, and Cochrane were searched from inception to July 2025 per PRISMA guidelines. Eligible studies included observational studies, case series, and case reports of patients with confirmed ATTR-CA undergoing TTR genetic testing and 99mTc scintigraphy.Results Nineteen studies (108 patients) met inclusion criteria. Thirteen pathogenic TTR variants were associated with low or absent uptake (Perugini grade 0–1); p.Val50Met, p.Phe84Leu, and p.Ser97Tyr were most consistently implicated, while p.Val142Ile showed false-negative results in ∼5–10% of carriers. In 11 of 13 variants, advanced structural cardiomyopathy was confirmed despite negative scintigraphy.Conclusions Bone scintigraphy has important limitations in specific hereditary TTR variants. A negative scan does not exclude cardiac involvement in genetically at-risk patients. Multimodal strategies including CMR and histological assessment are essential for timely diagnosis.
No takes yet. Share an insight, caveat, or question.
Giannino et al. (2026) conducted a systematic review in Hereditary transthyretin cardiac amyloidosis (ATTR-CA) (n=108). Pathogenic TTR genetic variants and 99mTc bone scintigraphy was evaluated on False-negative or low-grade tracer uptake on 99mTc bone scintigraphy (Perugini grade 0-1). Thirteen pathogenic TTR variants were associated with low or absent 99mTc bone scintigraphy uptake (Perugini grade 0-1) across 108 patients, with p.Val142Ile false-negative in 5-10% of carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: